A case report describes a case of hemolytic disease of the fetus and newborn (HDFN) in an AB blood type newborn due to A1 alloantibodies.
The risk of developing hemolytic disease of the fetus and newborn (HDFN) during pregnancy often results in a psychological burden on patients.
The combination of several medical indicators could be more effective for diagnosing HDFN than antibody testing alone.
The use of intravenous immunoglobulin in pregnancies at high risk of developing severe HDFN could significantly delay the onset of hemolysis.
The use of ABO+D+cEK match protocol before transfusion could prevent the formation of pathogenic antibodies that could lead to HDFN.
According to a recent study, IVIG may be an effective therapy alternative to intrauterine transfusions in HDFN caused by Kell-antigen incompatibility.
The L-score scoring system may potentially aid in differentiating between jaundice caused by HDFN from jaundice by other causes, the study showed.
A recent study shows antigen testing may be the most effective way of assessing the risk of developing hemolytic disease in the fetus and newborn (HDFN).
Middle cerebral artery Doppler sonography appears to be a reliable method for assessing fetal anemia in patients at risk of developing HDFN.
A novel variant of the RH antigen led a patient to develop hemolytic disease of the fetus and newborn (HDFN), according to a case report.
